LDN-57444 sensitizes hepatocellular carcinoma cells to sorafenib by promoting ferroptosis through histone deacetylase 2 (HDAC2) inhibition

Abstract Background Hepatocellular carcinoma (HCC) is still one of the leading causes of cancer-related mortality worldwide. Sorafenib is commonly used as first-line systemic treatment for advanced HCC, but the clinical benefits fall victim to either primary or acquired drug resistance. Modulating f...

Deskribapen osoa

Xehetasun bibliografikoak

Egile Nagusiak:	Jiunn-Chang Lin, Tun-Sung Huang, Yan-Bin Chen, Tung-Ying Chen, Pao-Shu Wu, Tsang-Pai Liu, Pei-Ming Yang
Formatua:	Artigo
Hizkuntza:	Inglês
Argitaratua:	BMC 2026-02-01
Saila:	Biology Direct
Gaiak:	LDN-57444 Sorafenib Hepatocellular carcinoma Ferroptosis HDAC2
Sarrera elektronikoa:	https://doi.org/10.1186/s13062-026-00735-1
Etiketak:	Etiketa erantsi Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!